Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;8(2):e001753.
doi: 10.1136/bmjdrc-2020-001753.

Long-term variability of glycemic markers and risk of all-cause mortality in type 2 diabetes: the Look AHEAD study

Affiliations

Long-term variability of glycemic markers and risk of all-cause mortality in type 2 diabetes: the Look AHEAD study

Arnaud D Kaze et al. BMJ Open Diabetes Res Care. 2020 Nov.

Abstract

Introduction: Glycemic variability may predict poor outcomes in type 2 diabetes. We evaluated the associations of long-term variability in glycosylated hemoglobin (HbA1C) and fasting plasma glucose (FPG) with cardiovascular disease (CVD) and death among individuals with type 2 diabetes.

Research design and methods: We conducted a secondary, prospective cohort analysis of the Look AHEAD (Action for Health in Diabetes) data, including 3560 participants who attended four visits (baseline, 12 months, 24 months, and 36 months) at the outset. Variability of HbA1C and FPG was assessed using four indices across measurements from four study visits. Participants without CVD during the first 36 months were followed for incident outcomes including a CVD composite (myocardial infarction, stroke, hospitalization for angina, and CVD-related deaths), heart failure (HF), and deaths.

Results: Over a median follow-up of 6.8 years, there were 164 deaths from any cause, 33 CVD-related deaths, 91 HF events, and 340 participants experienced the CVD composite. Adjusted HRs comparing the highest to lowest quartile of SD of HbA1C were 2.10 (95% CI 1.26 to 3.51), 3.43 (95% CI 0.95 to 12.38), 1.01 (95% CI 0.69 to 1.46), and 1.71 (95% CI 0.69 to 4.24) for all-cause mortality, CVD mortality, CVD composite and HF, respectively. The equivalent HRs for highest versus lowest quartile of SD of FPG were 1.66 (95% CI 0.96 to 2.85), 2.20 (95% CI 0.67 to 7.25), 0.94 (95% CI 0.65 to 1.35), and 2.05 (95% CI 0.80 to 5.31), respectively.

Conclusions: A greater variability in HbA1C was associated with elevated risk of mortality. Our findings underscore the need to achieve normal and consistent glycemic control to improve clinical outcomes among individuals with type 2 diabetes.

Keywords: cardiovascular system; diabetes mellitus; mortality; type 2.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Cumulative hazard of all-cause mortality (A), cardiovascular mortality (B), cardiovascular disease (CVD) composite (C), and incident heart failure (D) by quartile of SD of hemoglobin A1C. CVD composite was a composite of myocardial infarction, stroke, hospitalization for angina, and death for cardiovascular causes. hemoglobin A1C, glycosylated hemoglobin.

Similar articles

Cited by

References

    1. Menke A, Casagrande S, Geiss L, et al. . Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA 2015;314:1021–9. 10.1001/jama.2015.10029 - DOI - PubMed
    1. Virani SS, Alonso A, Benjamin EJ, et al. . Heart disease and stroke Statistics-2020 update: a report from the American heart association. Circulation 2020;141:e139–596. 10.1161/CIR.0000000000000757 - DOI - PubMed
    1. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72. 10.1056/NEJMoa0802987 - DOI - PubMed
    1. Duckworth W, Abraira C, Moritz T, et al. . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–39. 10.1056/NEJMoa0808431 - DOI - PubMed
    1. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59. 10.1056/NEJMoa0802743 - DOI - PMC - PubMed

Publication types